

First Quarter Fiscal Year Financial Report (Unaudited Statements)

Cone Health is an integrated health care delivery system serving its base of Greensboro NC, and surrounding counties through a system of hospitals, ambulatory care centers, physician offices and other related health care facilities. The primary and secondary service areas have almost one million residents for which Cone Health maintains a dominant market presence.

OPERATIONS

- 6 Hospitals 1,254 licensed beds
- 3 Ambulatory Surgery Centers
- 2 Nursing Homes 221 beds
- 1 Continuing Care Retirement Community
- 3 Ambulatory Care Campuses
- 149+ Outpatient Facilities
- 1,400+ Medical Staff, 500 employed

Over 12,000 employees

Triad Healthcare Network – clinically integrated with over 1000 affiliated physicians

50, 000 member Medicare ACO

14,000 member Medicare Advantage Plan

Management services agreement with Randolph Hospital

For the quarter ended December 31, 2017 the health network's consolidated operating income was \$13.8M and a margin of 2.9% compared to operating income of \$11.1M and a margin of 2.6% for fiscal year 2016. Excess of revenues over expenses were \$14.8M and an excess margin of 3.1% compared to \$15.2M and 3.5% for fiscal year 2017.

The first quarter of fiscal year 2018 continued the trend of higher outpatient volumes from fiscal year 2017, as net patient revenue increased 8.1% to \$434M. Compared to fiscal year 2017, inpatient volume increased by 1.5% to 15,037 fully offset by a large increase in observation cases. Acute length of stay decreased by 1.4% to 4.22 days although case mix increased from 1.61 to 1.66. Salaries and wages increased in line with patient volume, and benefits increased by 6.72% representing a higher cost of employee health and other employee benefits. Depreciation expense increased 7.90% to \$29.8M reflecting continued investment in facilities and information technology.

Supplies expense increased 7.1% principally driven by supplies for intensive inpatient surgeries, surgical implants and drug expenses for high cost cancer treatments, employee and specialty pharmacies and industry-wide inflation.

Non-operating income (other income) decreased by \$2.91M to positive \$2M as higher investment income was offset by increased expenses in a number on non-operating areas including Cone Health's Medicare Advantage Plan and operating expenses of the parent corporation.

Summary Statement of Operations (\$000)				
Fiscal Year 2018	YTD	Prior YTD		
Operating income	\$13,834	\$11,066		
Operating Margin %	2.9%	2.6%		
Operating EBIDA	\$47,324	\$42,012		
Operating EBIDA Margin %	9.8%	9.7%		
Excess of revenue over expenses	\$14,834	\$15,223		
Excess Margin %	3.07%	3.47%		
Change in Net Assets	\$37,151	\$35,363		

Surgical procedures increased to 10,456 (4,031 inpatient/6,425 outpatient) fiscal year to date, an increase of 1.4% over last fiscal year. Emergency department visits were up by 0.3%, offset by outpatient volumes. Physician outpatient services increased, driven by a number of factors including increased volume in the hospital setting, as well as volume from affiliated physicians acquired in previous years.

Operating State	tistics Fis	Fiscal Year to date 2018			
	Current Year	Prior year	% Variance		
Surgical Procedures	10,456	10,307	1.4%		
Deliveries	1,864	1,858	0.3%		
ED Visits	89,476	89,069	0.5%		
Outpatient Visits	180,514	181,412	-0.5%		
Physician Services					
Office Visits	193,597	181,348	6.8%		
Physician Hospital Visits	61,077	52,514	16.3%		
Procedures	125,888	104,458	20.5%		

Inpatient activity, measured by discharges, census and length of stay, increased over prior year. The increase in discharges of 223 was accompanied by an increase in observation cases of 139. Beds in service declined due to renovation and construction.

Hospital Statistics	Fiscal Year to date 2018			
	<u>Actual</u>	Prior year	% Variance	
Beds in Service	1,030	1,039	-0.9%	
Number of Inpatients (Discharges)	15,037	14,814	1.5%	
Average Length of Stay	4.22	4.16	-1.4%	
Average Daily Acute Census	690.4	669.3	3.2%	
Extended Care Census	287	287.0	0.0%	
Long Term Care Census	86.1	83.6	3.0%	

Balance sheet liquidity ratios strengthened in the quarter driven by positive cash flow as well strong investment performance. In December, Cone borrowed \$160 million to help fund large ongoing construction projects. Of that amount, \$27 million was released from restricted accounts in December with the remaining in assets whose use is restricted. Unrestricted cash and investments improved \$93 million during the quarter. The calendar year-to-date return on the system investment portfolio was 12.4% gain as the portfolio participated in the strong equity markets. As a result of positive cash flow, days cash improved to 225 days.

Third-Party Reimbursement and Sources of Payment of the Operating Corporation (NET)

	Fiscal Year to date	Fiscal Year	Fiscal Year
	2018	2017	2016
Medicare	33.9%	33.3%	34.0%
Medicaid	11.8%	12.8%	12.7%
Commercial & Managed Care	48.1%	47.8%	48.5%
Self-Pay	1.5%	1.4%	1.6%
Other	4.7%	4.7%	3.2%
Total	100.0%	100.0%	100.0%

Balance Sheet Summary of Key Metrics and Ratios as of December 31, 2017

	Actual	Prior Qtr.	Change	Prior FY
Cash and long-term investments (\$000)	\$1,070,072	\$1,028,642	\$41,430	\$1,028,642
Days cash on hand	225	225	0	225
Days in A/R	44	44	0	44
Cash to debt	159%	195%	-36%	195%
Debt to capitalization	28.61 %	24.28%	4.33%	24.28%
Annual debt service coverage ratio	6.28	6.57	-0.29	6.57

Debt Summary As of December 31, 2017

The following table shows debt under the Cone Master Trust Indenture, and excludes smaller direct loans and leases. Cone Health's debt is rated AA/Stable by FITCH Investors Service. In April, Standard & Poor's maintained its AA rating but added a negative outlook related to less favorable operating margins and expected capital expenditures and debt related to the construction of a new patient tower on The Moses H. Cone Memorial Hospital campus.

The Federal tax law legislation passed in late 2017 is expected to increase the cost of Cone's tax exempt debt by an aggregate amount of approximately 0.30%.

	Outstanding Debt Series as of December 31, 2017				
		Princ	ipal(\$)		
	Original	Outstanding	Current Rate	Maturity(FY)	Interest Mode
2001A	42,600,000	42,600,000	1.36%	2019	Weekly VRDB
2001B	42,600,000	42,600,000	1.38%	2019	Daily VRDB
2004A	47,500,000	46,855,000	1.45%	2017	Weekly VRDB
2011A	60,170,000	37,015,000	4.42%	2023	Fixed Rate
2011B	47,980,000	46,920,000	1.79%	2036	Windows Mode
2011C& D	100,000,000	95,750,000	1.51%	2021	Direct Placement
2013A,B & C	130,185,000	114,725,000	2.82%	2024	Direct Placement
2017 Note	50,000,000	50,000,000	4.33%	2046	Direct Placement
2017A	100,000,000	100,000,000	2.30%	2046	Direct Placement
2017B	60,000,000	60,000,000	1.28%	2041	Direct Placement
	681,035,000	628,280,000			
Other		37,900,000	2.61%	2026	Fixed

Rates include all related fees including remarketing, credit support and trustee.

VRDB maturities are the renewal date of credit support.

Direct placement maturities are the renewal date of rate agreements.

The 2001 A&B bonds are swapped to maturity at a rate of 3.43%.

The 2011B bonds are swapped to maturity at a rate of 2.097%.

In December 2017, Cone Health entered into two direct placement loans with two banks totaling \$160 million. \$100 million carries a ten year fixed rate of 2.29% and \$60 million carries a variable rate of 70% of 1 month libor plus 0.28%. Proceeds will be used to fund capital projects, specifically the new Women's and Children's pavilion on the Moses H. Cone Memorial Hospital campus and operative services improvements on the Wesley Long Community Hospital Campus.

In December 2016, Cone Health executed a \$50 million 30-year term loan (2017Note) at a fixed rate of 4.33%. These funds, subsequent to Dec. 31, were deposited into the closed defined benefit plan. At December 31, the funding level was approximately 96%. Cone Health has developed a journey plan with respect to the pension to begin immunizing the plan from changes in interest rates, and as of December 31, 65% of assets were placed into hedging assets to offset changes in liabilities due to interest rate changes.

The 2004A and 2011B bonds are supported with Cone Health's liquidity that totaled \$908 million at December 31, 2017, not including funds of the Cone Foundation and Impact Alamance Foundation. Two lines of credit totaling \$97.5 million are also available to support outstanding indebtedness. The availability of Cone Health's liquidity is shown in the following table.

On Oct. 6, 2016, Cone Health entered into a forward dated fixed rate swap to hedge interest on an expected debt issuance in 2018. The notional amount is \$100 million, fixed rate of 1.336 versus 70% of 1 month LIBOR.

Cone Health Liquidity As of December 31, 2017 available to support debt payments and self-supported bond exposure (excluding Foundation assets)					
			Funds Availability		
	Market Value				
Type	(Millions)	<u>1-Day</u>	<u>Under 1-Week</u>	Over 1-Week	
Deposits at Banks	\$43.6	\$43.6			
Bond Funds	\$175.3	\$84.3	\$91.0	\$0	
Equity Funds	\$403.4	\$41.5	\$73.2	\$288.7	
Other Funds	\$286.2	\$32.2	\$11.8	\$242.2	
Total Liquid Assets	\$908.5	\$201.6	\$176.0	\$530.9	
Bank Lines of Credit	\$97.5	\$97.5			
Total Liquidity	\$1,006.0	\$299.1	\$176.0	\$530.9	

\$47.5 million in bank lines of credit are only available to support a failed remarketing of the 2004A bonds. The remaining \$50 million line is available for general working capital purposes.

The values of investments in the above chart are market values for Cone Health assets, not including foundation assets. The market values are higher than financial statement values because certain investments in the financial statements are carried at cost, not market value.

Contact Information

John Miller CIO and Treasurer John.Miller@ConeHealth.com Andy Barrow **VP** Finance

Andy.Barrow@ConeHealth.com

Ratio Methodology

Long Term Debt Service Coverage Ratio Excess of Revenues + Depreciation+ Interest / Interest + Principal

For interim periods, Excess of Revenues and Depreciation are annualized, Interest and Principal are estimated for the full year.

Interest Expense includes remarketing, credit support, trustee fees and other related expenses.

Days Cash on Hand Unrestricted Cash and Investments / Operating Expense less Depreciation For interim periods, the calculation is based on actual number of days in the period.

Short and Long Term Debt + Leases / Total Capitalization Debt to Capital Ratio

Total Capitalization is Short and Long Term Debt + Leases + Unrestricted Net Assets

Max Annual Debt Service Coverage Ratio

Same as the Long Term Debt Service Coverage Ratio, except the interest and principal is the largest scheduled debt service amount estimated for each future year. Variable rate debt is estimated using the 10 year average of SIFMA plus related expenses.

Cash to Debt Ratio Unrestricted Cash and Investments / Short and Long Term Debt + Leases

Cone Health Consolidated Balance Sheets

Assets	December 31, 2017	Audited September 30, 2017	Liabilities and Net Assets	December 31, 2017	Audited September 30, 2017
Current Assets			Current Liabilities		
	\$ 69.265.135	\$ 57.808.044	Accrued Payroll	\$ 85.100.778	\$ 92.377.221
Short-Term Investments	26.976.401	26.802.222	Accounts Pavable	69.929.524	78.196.469
Patient Receivables (net) (Note 1)	209.840.836	198.787.064	PAL & Retirement	30.563.283	31,227,502
Other Receivables	54.144.351	52.469.211	Medical Claims IBNR	11.822.792	11,822,792
Inventories	32,533,802	31.435.086	Bonds Payable (Note 5)	12.545.000	12,525,000
Prepaid Expenses	16,280,685	16.571.150	Short Term Debt, Line of Credit (Note 5)	176,851,449	179,462,643
Other Current Assets	17,771,416	20,422,377	Other Current Liabilities	94,317,059	96,389,433
Total Current Assets	426,812,626	404,295,154	Total Current Liabilities	481,129,885	502,001,060
Plant and Property (net) Land and Land Improvements Building and Fixed Equipment Moveable Equipment Real Estate Construction/Equipment in Progress	72,110,683 728,061,008 205,933,728 12,180,925 1,018,286,344 64,937,134	71,038,285 715,400,411 209,032,116 12,469,247 1,007,940,059 79,182,090	Debt and Other Liabilities Bonds Payable (Note 5) Long Term Debt (Note 5) Capital Lease Obligation Other Non-Current Liabilies Total Liabilities	438,095,503 38,498,822 9,511,003 121,551,062 1,088,786,275	284,200,131 39,623,943 10,526,201 115,411,401 951,762,736
Total Plant and Property (Note 2) Other Non Current Assets	1,083,223,478	1,087,122,149	Net Assets		
Marketable Securities (Note 3)	992.661.188	962.807.860	Net Assets Unrestricted	1.679.004.959	1.641.588.824
Joint Ventures (Note 4)	992,661,188 55,042,892	53,229.030	Noncontrolling Interest	96,928	913,098
Investment in Unrelated Parties	55,042,692	53,229,030	Total Unrestricted Net Assets	1.679.101.887	1.642.501.922
Trustee held bond funds	133.347.677	9,035,903	Total Unirestricted Net Assets	1,679,101,667	1,642,501,922
Investments	1,181,639,781	1,025,660,817			
			Temporarily Restricted	12,645,240	12,037,484
Deferred Costs	92,384	88,566	Total Restricted Net Assets	12,645,240	12,037,484
Other Assets	79,035,795	79,406,118			
Goodwill	9,729,338	9,729,338	Total Net Assets	1,691,747,127	1,654,539,406
Total Other Non-Current Assets	88,857,517	89,224,022			
TOTAL ASSETS	\$ 2,780,533,402	\$ 2,606,302,142	TOTAL LIAB. AND NET ASSETS	\$ 2,780,533,402	\$ 2,606,302,142

Cone Health Consolidated Statements of Operations

REVENUE ACTUAL 12/31/17 ACTUAL 12/31/16 ActUAct 7/8 v/vs v/vs v/vs v/vs v/vs v/vs v/vs v/		YEAR-TO-DATE			
Patient Service Revenue (net of contractual allowances and discounts) \$ 473,358,341 \$ 437,807,208 8.12%					
Same	REVENUE				
Provision for bad debts (Note 1) 39,440,772 36,475,512 8.13% Net Patient Service Revenue (Note 2) 433,917,569 401,331,696 8.12% Other Operating Revenue 21,618,841 19,109,822 13.13% Premium Revenue 26,431,340 13,641,184 93.76% TOTAL OPERATING REVENUES 481,967,750 434,082,702 11.03% EXPENSE 541,967,750 434,082,702 11.03% EXPENSE 581,342,550 481,967,750 434,082,702 11.03% Fringe Benefits 60,437,915 56,633,980 6.72% Purchased Personnel 4,369,856 3,342,588 30,73% Medical Claims Expense 22,932,618 11,035,810 107,80% Supplies 89,777,317 83,441 17,475,165 11,62% Other Operating Expense 79,781,721 71,475,165 11,62% Interest Expense 3,646,285 3,286,638 10,94% Depreciation/Amortization 29,843,568 27,659,801 7,90% TOTAL OPERATIOR 7,057,276 <td< td=""><td>Patient Service Revenue (net of contractual</td><td></td><td></td><td></td><td></td></td<>	Patient Service Revenue (net of contractual				
Net Patient Service Revenue (Note 2) 433,917,569 401,331,696 8.12% Other Operating Revenue Premium Revenue 21,618,841 19,109,822 13.13% Premium Revenue 26,431,340 13,641,184 93.76% TOTAL OPERATING REVENUES 481,967,750 434,082,702 11.03% EXPENSE 8 177,344,350 165,772,546 6.98% Fringe Benefits 60,437,915 56,633,980 6.72% Purchased Personnel 4,369,856 3,342,588 30,73% Medical Claims Expense 22,932,618 11,035,810 107,80% Supplies 89,777,317 83,810,484 71.2% Other Operating Expense 79,781,721 71,457,165 11.62% Interest Expense 3,646,285 3,286,638 10,94% Depreciation/Amortization 29,843,568 27,659,801 7,90% TOTAL OPERATIOR EXPENSE 468,133,630 423,017,012 10.67% INCOME FROM OPERATIONS 13,834,120 11,065,690 25.02% OTHER INCOME 2,390,338 571,839	allowances and discounts)	\$	473,358,341 \$	437,807,208	8.12%
Other Operating Revenue Premium Revenue 21,618,841 19,109,822 13.13% Premium Revenue TOTAL OPERATING REVENUES 481,967,750 434,082,702 110.3% EXPENSE Salaries and Wages Fringe Benefits 177,344,350 165,772,546 6.98% Fringe Benefits 60,437,915 56,633,380 6.72% Purchased Personnel 4,369,856 3,342,588 30,73% Medical Claims Expense 22,932,618 11,035,810 107,80% Supplies 89,777,317 83,810,484 7,12% Other Operating Expense 79,781,721 71,475,165 11,62% Interest Expense 3,646,285 3,286,638 10,94% Depreciation/Amortization 29,843,568 27,659,801 7,90% TOTAL OPERATING EXPENSE 466,133,630 423,017,012 10,67% INCOME FROM OPERATIONS 13,834,120 11,065,690 25,02% OTHER INCOME 10,751,286 -34,36% Joint Venture Income (Note 3) 7,057,276 10,751,286 -34,36% Joint Venture Income (Note 4) 7,380,331 6,40	Provision for bad debts (Note 1)		39,440,772	36,475,512	-8.13%
Premium Revenue 26,431,340 13,641,184 93.76% TOTAL OPERATING REVENUES 481,967,750 434,082,702 11.03% EXPENSE Salaries and Wages 177,344,350 165,772,546 6.98% Fringe Benefits 60,437,915 56,633,980 6.72% Fringe Exponse 22,932,618 11,035,810 107,80% Fringe Expense 89,777,317 83,810,484 7.12% Fringe Expense 79,781,721 71,475,165 11,62% Fringe Expense 79,781,721 71,475,165 11,62% Fringe Expense 79,843,568 27,659,801 7.90% Fringe Expense 79,843,568 79,833 318,01% Fringe Expense 79,843,4120 11,065,690 25.02% Fringe Expense 79,72,76 10,751,286 -34.36% 79,00% Fringe Expense 79,72,776 79,00% 79	Net Patient Service Revenue (Note 2)		433,917,569	401,331,696	8.12%
Premium Revenue 26,431,340 13,641,184 93.76% TOTAL OPERATING REVENUES 481,967,750 434,082,702 11.03% EXPENSE Salaries and Wages 177,344,350 165,772,546 6.98% Fringe Benefits 60,437,915 56,633,980 6.72% Fringe Exponse 22,932,618 11,035,810 107,80% Fringe Expense 89,777,317 83,810,484 7.12% Fringe Expense 79,781,721 71,475,165 11,62% Fringe Expense 79,781,721 71,475,165 11,62% Fringe Expense 79,843,568 27,659,801 7.90% Fringe Expense 79,843,568 79,833 318,01% Fringe Expense 79,843,4120 11,065,690 25.02% Fringe Expense 79,72,76 10,751,286 -34.36% 79,00% Fringe Expense 79,72,776 79,00% 79	Other Operating Revenue		21.618.841	19.109.822	13.13%
TOTAL OPERATING REVENUES					
Salaries and Wages 177,344,350 165,772,546 6.98% Fringe Benefits 60,437,915 56,633,980 6.72% Purchased Personnel 4,369,856 3,342,588 30.73% Medical Claims Expense 22,932,618 11,035,810 107.80% Supplies 89,777,317 83,810,484 7.12% Other Operating Expense 79,781,721 71,475,165 11.62% Interest Expense 3,646,285 3,286,638 10.94% Depreciation/Amortization 29,843,568 27,659,801 7.90% TOTAL OPERATING EXPENSE 468,133,630 423,017,012 10.67% INCOME FROM OPERATIONS 13,834,120 11,065,690 25.02% OTHER INCOME 10,vertical Company 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 3) 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 4) 2,390,338 571,839 318.01% Other Expense (Note 4) (7,438,031) (6,408,615) -59.11% EXCESS OF REVENUES OVER EXPENSE 15,843,703	TOTAL OPERATING REVENUES				
Salaries and Wages 177,344,350 165,772,546 6.98% Fringe Benefits 60,437,915 56,633,980 6.72% Purchased Personnel 4,369,856 3,342,588 30.73% Medical Claims Expense 22,932,618 11,035,810 107.80% Supplies 89,777,317 83,810,484 7.12% Other Operating Expense 79,781,721 71,475,165 11.62% Interest Expense 3,646,285 3,286,638 10.94% Depreciation/Amortization 29,843,568 27,659,801 7.90% TOTAL OPERATING EXPENSE 468,133,630 423,017,012 10.67% INCOME FROM OPERATIONS 13,834,120 11,065,690 25.02% OTHER INCOME 10,vertical Company 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 3) 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 4) 2,390,338 571,839 318.01% Other Expense (Note 4) (7,438,031) (6,408,615) -59.11% EXCESS OF REVENUES OVER EXPENSE 15,843,703	EXPENSE				
Fringe Benefits 60,437,915 56,633,980 6.72% Purchased Personnel 4,369,856 3,342,588 30.73% Medical Claims Expense 22,932,618 11,035,810 107,80% Supplies 89,777,317 83,810,484 7.12% Other Operating Expense 79,781,721 71,475,165 11,62% Interest Expense 3,646,285 3,286,638 10,94% Depreciation/Amortization 29,843,568 27,659,801 7.90% TOTAL OPERATING EXPENSE 468,133,630 423,017,012 10,67% INCOME FROM OPERATIONS 13,834,120 11,065,690 25.02% OTHER INCOME 1nvestment Income (Note 3) 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 4) 2,390,338 571,839 318.01% Other Expense (Note 4) (7,438,031) (6,408,615) -16,06% Total Other Income (Expense) 2,009,583 4,914,510 -59,11% EXCESS OF REVENUES OVER EXPENSE 15,843,703 15,980,200 -0.85% Non-controlling Interest Expense (Income)			177.344.350	165.772.546	6.98%
Purchased Personnel 4,369,856 3,342,588 30.73% Medical Claims Expense 22,932,618 11,035,810 107.80% Supplies 89,777,317 83,810,484 7.12% Other Operating Expense 79,781,721 71,475,165 11.62% Interest Expense 3,646,285 3,286,638 10.94% Depreciation/Amortization 29,843,568 27,659,801 7.90% TOTAL OPERATING EXPENSE 468,133,630 423,017,012 10.67% INCOME FROM OPERATIONS 13,834,120 11,065,690 25.02% OTHER INCOME 1 10,751,286 -34.36% Joint Venture Income (Note 3) 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 4) 2,390,338 571,839 318.01% Other Expense (Note 4) (7,438,031) (6,408,615) -16.06% Total Other Income (Expense) 2,009,583 4,914,510 -59.11% EXCESS OF REVENUES OVER EXPENSE 15,843,703 15,980,200 -0.85% EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275<					
Medical Claims Expense 22,932,618 11,035,810 107.80% Supplies 89,777,317 83,810,484 7.12% Other Operating Expense 79,781,721 71,475,165 11.62% Interest Expense 3,646,285 3,286,638 10,94% Depreciation/Amortization 29,843,568 27,659,801 7.90% TOTAL OPERATIORS 468,133,630 423,017,012 10.67% INCOME FROM OPERATIONS 13,834,120 11,065,690 25.02% OTHER INCOME Investment Income (Note 3) 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 4) 2,390,338 571,839 318.01% Other Expense (Note 4) (7,438,031) (6,408,615) -16.06% Total Other Income (Expense) 2,009,583 4,914,510 -59.11% EXCESS OF REVENUES OVER EXPENSE 15,843,703 15,980,200 -0.85% EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275 -2.55% Change in Net Unrealized Gains and (Losses) on Investments (Note 3) 22,316,730 20,140,098 10.81%					
Supplies 89,777,317 83,810,484 7.12% Other Operating Expense 79,781,721 71,475,165 11.62% Interest Expense 3,646,285 3,286,638 10.94% Depreciation/Amortization 29,843,568 27,659,801 7.90% TOTAL OPERATING EXPENSE 468,133,630 423,017,012 10.67% INCOME FROM OPERATIONS 13,834,120 11,065,690 25.02% OTHER INCOME 10,757,276 10,751,286 -34.36% Joint Venture Income (Note 3) 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 4) (7,438,031) (6,408,615) -16.06% Total Other Income (Expense) 2,009,583 4,914,510 -59.11% EXCESS OF REVENUES OVER EXPENSE 15,843,703 15,980,200 -0.85% Non-controlling Interest Expense (Income) 1,009,232 756,925 -33.33% EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275 -2.55% Change in Net Unrealized Gains and (Losses) on Investments (Note 3) 22,316,730 20,140,098 10.81%	Medical Claims Expense				
Other Operating Expense Interest E	·				
Interest Expense 3,646,285 3,286,638 10.94% Depreciation/Amortization 29,843,568 27,659,801 7.90% TOTAL OPERATING EXPENSE 468,133,630 423,017,012 10.67% INCOME FROM OPERATIONS 13,834,120 11,065,690 25.02% Investment Income (Note 3) 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 4) 2,390,338 571,839 318.01% Other Expense (Note 4) (7,438,031) (6,408,615) -16.06% Total Other Income (Expense) 2,009,583 4,914,510 -59.11% EXCESS OF REVENUES OVER EXPENSE BEFORE NONCONTROLLING INTEREST 15,843,703 15,980,200 -0.85% EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275 -2.55% Change in Net Unrealized Gains and (Losses) on Investments (Note 3) 22,316,730 20,140,098 10.81%			79,781,721		11.62%
TOTAL OPERATING EXPENSE 468,133,630 423,017,012 10.67% INCOME FROM OPERATIONS 13,834,120 11,065,690 25.02% OTHER INCOME Investment Income (Note 3) 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 4) 2,390,338 571,839 318.01% Other Expense (Note 4) (7,438,031) (6,408,615) -16.06% Total Other Income (Expense) 2,009,583 4,914,510 -59.11% EXCESS OF REVENUES OVER EXPENSE 15,843,703 15,980,200 -0.85% Non-controlling Interest Expense (Income) 1,009,232 756,925 -33.33% EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275 -2.55% Change in Net Unrealized Gains and (Losses) on Investments (Note 3) 22,316,730 20,140,098 10.81%			3,646,285	3,286,638	10.94%
INCOME FROM OPERATIONS 13,834,120 11,065,690 25.02%			29,843,568	27,659,801	7.90%
OTHER INCOME Investment Income (Note 3) 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 4) 2,390,338 571,839 318.01% Other Expense (Note 4) (7,438,031) (6,408,615) -16.06% Total Other Income (Expense) 2,009,583 4,914,510 -59.11% EXCESS OF REVENUES OVER EXPENSE 15,843,703 15,980,200 -0.85% Non-controlling Interest Expense (Income) 1,009,232 756,925 -33.33% EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275 -2.55% Change in Net Unrealized Gains and (Losses) on Investments (Note 3) 22,316,730 20,140,098 10.81%	TOTAL OPERATING EXPENSE		468,133,630	423,017,012	10.67%
Investment Income (Note 3) 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 4) 2,390,338 571,839 318.01% Other Expense (Note 4) (7,438,031) (6,408,615) -16.06% Total Other Income (Expense) 2,009,583 4,914,510 -59.11% EXCESS OF REVENUES OVER EXPENSE BEFORE NONCONTROLLING INTEREST 15,843,703 15,980,200 -0.85%	INCOME FROM OPERATIONS		13,834,120	11,065,690	25.02%
Investment Income (Note 3) 7,057,276 10,751,286 -34.36% Joint Venture Income (Note 4) 2,390,338 571,839 318.01% Other Expense (Note 4) (7,438,031) (6,408,615) -16.06% Total Other Income (Expense) 2,009,583 4,914,510 -59.11% EXCESS OF REVENUES OVER EXPENSE BEFORE NONCONTROLLING INTEREST 15,843,703 15,980,200 -0.85%	OTHER INCOME				
Doint Venture Income (Note 4) 2,390,338 571,839 318.01%			7.057.276	10.751.286	-34.36%
Other Expense (Note 4) (7,438,031) (6,408,615) -16.06% Total Other Income (Expense) 2,009,583 4,914,510 -59.11% EXCESS OF REVENUES OVER EXPENSE BEFORE NONCONTROLLING INTEREST 15,843,703 15,980,200 -0.85% Non-controlling Interest Expense (Income) 1,009,232 756,925 -33.33% EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275 -2.55% Change in Net Unrealized Gains and (Losses) on Investments (Note 3) 22,316,730 20,140,098 10.81%					
Total Other Income (Expense) 2,009,583 4,914,510 -59.11% EXCESS OF REVENUES OVER EXPENSE BEFORE NONCONTROLLING INTEREST 15,843,703 15,980,200 -0.85% Non-controlling Interest Expense (Income) 1,009,232 756,925 -33.33% EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275 -2.55% Change in Net Unrealized Gains and (Losses) on Investments (Note 3) 22,316,730 20,140,098 10.81%					
BEFORE NONCONTROLLING INTEREST 15,843,703 15,980,200 -0.85% Non-controlling Interest Expense (Income) 1,009,232 756,925 -33.33% EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275 -2.55% Change in Net Unrealized Gains and (Losses) on Investments (Note 3) 22,316,730 20,140,098 10.81%			, , , , , , , , , , , , , , , , , , , ,		
BEFORE NONCONTROLLING INTEREST 15,843,703 15,980,200 -0.85% Non-controlling Interest Expense (Income) 1,009,232 756,925 -33.33% EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275 -2.55% Change in Net Unrealized Gains and (Losses) on Investments (Note 3) 22,316,730 20,140,098 10.81%	EXCESS OF REVENUES OVER EXPENSE				
EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275 -2.55% Change in Net Unrealized Gains and (Losses) 22,316,730 20,140,098 10.81%			15,843,703	15,980,200	-0.85%
EXCESS OF REVENUES OVER EXPENSE 14,834,471 15,223,275 -2.55% Change in Net Unrealized Gains and (Losses) 22,316,730 20,140,098 10.81%					
Change in Net Unrealized Gains and (Losses) on Investments (Note 3) 22,316,730 20,140,098 10.81%	Non-controlling Interest Expense (Income)		1,009,232	756,925	-33.33%
on Investments (Note 3) 22,316,730 20,140,098 10.81%	EXCESS OF REVENUES OVER EXPENSE		14,834,471	15,223,275	-2.55%
INCREASE IN UNRESTRICTED NET ASSETS \$ 37,151,201 \$ 35,363,373 5.06%			22,316,730	20,140,098	10.81%
	INCREASE IN UNRESTRICTED NET ASSETS	\$	37,151,201 \$	35,363,373	5.06%

Cone Health Consolidated Statement of Changes in Net Assets

				Audited
	Dece	mber 31, 2017	Sept	ember 30, 2017
UNRESTRICTED NET ASSETS:			-	
Excess of revenues over expenses from consolidated operations	\$	15,843,703	\$	70,851,374
Change in net unrealized gains and losses on investments		21,226,775		57,585,101
Pension-related changes other than net periodic benefit cost				16,424,973
Change in the fair value of the floating-to-fixed swap agreement		1,089,955		18,265,059
Acquistion of HTA noncontrolling interest				(17,600,000)
Other changes in net assets		(1,560,468)		(4,228,476)
Increase in unrestricted net assets		36,599,965		141,298,031
TEMPORARILY RESTRICTED NET ASSETS:				
Other changes in net assets		607,756		921,573
Increase in temporarily restricted net assets		607,756		921,573
INCREASE IN NET ASSETS	\$	37,207,721	\$	142,219,604

Cone Health Consolidated Statements of Cash Flows

	December 31, 2017	Audited September 30, 2017
CASH FLOWS FROM OPERATING AND NON OPERATING ACTIVITIES		
CASH PROVIDED BY OPERATING ACTIVITIES		
Increase in net assets	\$ 37,207,721	\$ 142,219,604
Adjustments to reconcile revenue and gains in excess of expenses and losses to		
new cash provided by operating activities		
Change in net unrealized gains and losses on investments	(21,226,775)	(57,585,101)
Change in fair value of the floating-to-fixed swap agreement	(1,089,955)	(18,265,059)
Net realized gain on sale of investments	(3,508,244)	(29,037,350)
Depreciation and amortization	29,843,568	115,466,763
Provision for uncollectible accounts	39,440,772	145,691,014
Accumulated or Other Comprehensive Income (FAS 158 - pension)	-	(16,424,973)
Loss on disposal of property and equipment	34,559	2,894,348
Equity in earnings of unconsolidated entities	(2,390,338)	(4,364,272)
Distributions from unconsolidated entities	576,476	3,398,662
Distributions to noncontrolling interests	1,825,402	6,587,834
Purchase of noncontrolling interest	-	17,600,000
Changes to medical claims IBNR in Care-n-Care of NC	-	7,170,591
(Increase) Decrease in patient accounts receivable	(50,494,544)	(114,868,515)
(Increase) Decrease in prepaids and other receivables	(1,530,765)	(16,538,999)
(Increase) Decrease in inventory	(1,098,716)	(2,562,039)
Increase (Decrease) in accounts payable and accrued expenses	(17,322,313)	37,734,001
Contribution to pension liability	-	(58,750,000)
(Increase) Decrease in other operating assets and liabilities (net)	6,681,925	3,682,204
Net cash provided by operating activities and gains and losses	16,948,773	164,048,713
CASH FLOWS FROM INVESTING ACTIVITIES		
(Additions) to Property, Plant and Equipment	(26,209,936)	(128,675,557)
(Increase) in investment portfolios	(127,082,439)	(5,097,208)
Restriction of funds in Care-n-Care of NC, Inc.	-	(10,187,971)
Net cash used in investing activities	(153,292,375)	(143,960,736)
·		
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from debt issuance	159,484,737	130,397,444
Repayments of debt	(9,346,316)	(92,357,305)
Purchase of noncontrolling interest	-	(12,000,000)
Distributions to noncontrolling interest	(1,825,402)	(6,587,834)
Payments on capital lease obligations	(512,326)	(2,068,979)
Net cash provided by financing activities	147,800,693	17,383,326
NET INCREASE IN CASH AND CASH EQUIVALENTS	11,457,091	37,471,303
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	57,808,044	20,336,741
CASH AND CASH EQUIVALENTS, END OF PERIOD	\$ 69,265,135	\$ 57,808,044